Navigation Links
Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
Date:5/6/2008

TORONTO, May 6 /PRNewswire/ - Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.

Utilizing enzyme-based technology developed at Thermo Fisher Scientific's Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (poly-I) and poly-cytosine (poly-C) in accordance with cGMP (current good manufacturing practice) regulations. Poly-I and Poly-C are polynucleotides that are used as adjuvants, or catalysts, to stimulate an immune response when combined with other substances in a drug. Dalton will supply these polynucleotides to Oncovir, Inc., an innovative pharmaceutical company that will use Poly-I and Poly-C in vaccine development.

"We are delighted to have this opportunity to work with Thermo Fisher Scientific in order to commercialize their novel biopolymers," said Peter Pekos, president and CEO of Dalton Pharma Services. "The agreement is timely due to an increased demand for commercial quantities of these molecules as adjuvants for new vaccines. And, this partnership recognizes Dalton's expertise in cGMP manufacturing and analysis of complex molecules under cGMP conditions."

"By working with partners like Dalton Pharma Services, our innovative technology is finding its way into new and exciting therapeutics," said Mitch Kennedy, global vice president and general manager of Thermo Fisher Scientific's Genomics business. "Ultimately, this allows Thermo Fisher Scientific to advance our mission as a company, which is to enable our customers to make the world healthier, cleaner and safer."

About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
2. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
4. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Benda Pharmaceutical Files Amendment To Form S-1
6. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
7. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
8. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
9. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):